Biotech
Kailera Therapeutics
Kailera Therapeutics raises $400M Series A at $1.5B valuation
$400M
Total Raised
Series A
Latest Round
2024
Founded
80+
Employees
Cambridge, MA
1 min read
Quick Facts
Valuation
$1.5B
Latest Round Size
$400M
Latest Round Date
October 2024
Kailera Therapeutics: Series A Funding Round
Kailera Therapeutics has successfully raised $400M in Series A funding, reaching a valuation of $1.5B.
Company Overview
Developing obesity therapeutics with acquired pipeline
Funding Details
The Series A round was led by Atlas Venture, with participation from Bain Capital Life Sciences.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2024
- Employees: 80+
- Category: Biotech
Investment
Kailera Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Atlas Venture: Verified investor in Series A
- Bain Capital Life Sciences: Verified investor in Series A
Key Investors
Atlas Venture
Lead Investor
Verified investor in Series A
Bain Capital Life Sciences
Investor
Verified investor in Series A
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M